US Stock MarketDetailed Quotes
LIXT Lixte Biotechnology
- 1.6300
- +0.1100+7.24%
Close Nov 22 16:00 ET
3.67MMarket Cap-942P/E (TTM)
1.7900High1.5700Low28.31KVolume1.5900Open1.5200Pre Close46.48KTurnover1.43%Turnover RatioLossP/E (Static)2.25MShares4.420052wk High-1.72P/B3.22MFloat Cap1.310052wk Low--Dividend TTM1.98MShs Float71.9000Historical High--Div YieldTTM14.47%Amplitude1.3100Historical Low1.6410Avg Price1Lot Size
About Lixte Biotechnology Company
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.
Company Profile
SymbolLIXT
Company NameLixte Biotechnology
Listing DateNov 25, 2020
Issue Price0.98
Founded2005
CEOMr. Bastiaan van der Baan
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address680 East Colorado Boulevard,Suite 180
CityPasadena
ProvinceCalifornia
CountryUnited States of America
Zip Code91101
Phone1-631-830-7092
Websitehttp://www.lixte.com
Company Executives
- Name
- Position
- Salary
- Bastiaan van der Baan
- Chairman of the Board, President and Chief Executive Officer
- 66.61K
- Robert Neal Weingarten
- Vice President and Chief Financial Officer
- 175.00K
- Eric J. Forman, J.D.
- Vice President and Chief Operating Officer
- 200.00K
- Dr. Jan H.M. Schellens
- Chief Medical Officer
- --
- Dr. Stephen J. Forman
- Independent Director
- 85.84K
- Dr. Rene Bernards
- Independent Director
- 133.87K
- Regina Brown
- Independent Director
- 78.13K
- Dr. Yun Yen, M.D.
- Independent Director
- 78.13K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data